SCHEMBL5157933

SCHEMBL5157933

COc1ccc(-c2c(-c3cc(Cl)ccc3O)c3cc(C(F)(F)F)ccc3[nH]c2=O)cc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 9/20 0.60
CYP3A4 P08684 3/20 0.59
CYP2C19 P33261 3/20 0.59
CYP2D6 P10635 2/20 0.59
CYP1A2 P05177 1/20 0.59
BIRC5 O15392 1/20 0.42
GSK3B P49841 2/20 0.41
CDK5 Q00535 2/20 0.41
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CDK5R1 Q15078 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
MAP2 P11137 2/20 0.40
KCNQ3 O43525 1/20 0.39
KCNQ2 O43526 1/20 0.39
KCNQ4 P56696 1/20 0.39
KCNMA1 Q12791 1/20 0.39
KCNQ5 Q9NR82 1/20 0.39
EEF2K O00418 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5159715 0.85 CYP2C9 (0.66) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5159446 0.83 CYP2C9 (0.66) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5160093 0.83 CYP2C9 (0.64) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5157642 0.83 CYP2C9 (0.65) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5157936 0.81 CYP2C9 (0.40) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5157444 0.81 CYP2C9 (0.59) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5160611 0.80 CYP2C9 (0.61) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5159391 0.80 CYP2C9 (0.70) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6544425 0.79 CYP2C9 (0.72) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL5418072 0.79 CYP2C9 (0.70) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1133474-B1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2007-02-21 EP claimed
US-6184231-B1 NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION BRISTOL-MYERS SQUIBB 2001-02-06 US claimed
EP-1133474-B1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2007-02-21 EP disclosed
EP-1133474-A4 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2005-02-16 EP disclosed
EP-1133474-A1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-09-19 EP disclosed
US-6184231-B1 NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION BRISTOL-MYERS SQUIBB 2001-02-06 US disclosed
WO-2000034244-A1 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-06-15 WO disclosed